FEMY logo

FEMASYS INC

FEMYNASDAQ
🏆 #4782 by market capEarnings Nov 17US Equity
$1.39▲ $0.00 (+0.00%)
Pre-market · at close
🔔
Track FEMY
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.0%
7d▼ 12.0%
14d▼ 19.4%
30d▼ 34.4%
ytd▼ 87.9%
1y▼ 89.1%
🏦Market Cap
$12M
Small Cap
📈Revenue Growth (YoY)
40.8%
High Growth
📊Gross Margin
52.2%
Healthy
💵FCF Margin
-788.0%
Thin
⚖️P/S Ratio
5.1x
Fair
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.39 – $1.42
52-Week Range
$1.32 – $22.20
Volume (shares)
978
Avg Volume (shares)
—
Shares Outstanding
8.4M
Next Earnings
2026-11-17

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$331,827
P/E Ratio
-0.3
P/S Ratio
5.1x
EPS (TTM)
$-3.66
Dividend Yield
0.00%
Dilution (1yr)
+73.4%
FEMY logo

FEMASYS INC

FEMY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2M▲ +40.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
62.0%▼ −6.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$18M▼ −1.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$19M▼ −4.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.0M▲ +73.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▲ +$9M YoY
StockOtter · stockotter.space

About FEMASYS INC

Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
9 analysts
Strong Buy2
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.